CDK6 and acute lymphoblastic leukemia: PROTAC YX-2-107 was demonstrated to inhibit CDK6’s kinase-independent function, thus more efficiently suppressing Ph+-ALL cells compared to palbociclib (inactive to CDK6’s kinase-independent function) [78].